Zydus Lifesciences gains US FDA priority review for saroglitazar in PBC, strengthening its specialty pipeline amid rising global demand for liver disease therapies.
FDA inspection flags data integrity and manufacturing lapses at Dabur plant, raising compliance risks, export concerns, and quality scrutiny in the US market.
China’s biotech boom drives $10.5B Pfizer-Innovent deal, highlighting global shift to innovation while exposing India’s gaps in research, funding, and licensing.
Cipla targets 50 global filings, focusing on innovation, biosimilars, and complex generics to expand US and Europe presence and strengthen chronic therapy leadership.
Novo Nordisk’s Wegovy has received approval in India for teenagers struggling with obesity, opening a new treatment option for young patients aged 12 years and above. The approval of Novo Nordisk’s Wegovy in India for teens battling obesity come...
AI-generated fake prescriptions fueling misuse of antibiotics and psychotropic drugs are becoming a growing concern in India, raising serious questions about patient safety and online medicine sales. Health experts and chemists warn that fak...
Hikal posts Q4 FY26 profit recovery driven by crop protection growth and cost actions, despite USFDA impact and one-time charges, while maintaining dividend payout.
India clears Wockhardt’s Zaynich, a novel antibiotic for drug-resistant infections, backed by strong Phase 3 data, offering an effective treatment option for complicated UTIs and severe Gram-negative cases.
Tata-backed MedTherapy claims a CAR-T breakthrough, marking what could be a major shift in cancer treatment manufacturing. The company says it can now produce CAR-T therapy within just 24 hours, compared to the several weeks the process usual...
The article explores GLP-1 pathways, berberine, and Metaberine in metabolic health, highlighting multi-pathway, science-backed solutions for better glycemic control and long-term metabolic balance.